SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0001144204-16-081316
Filing Date
2016-02-12
Accepted
2016-02-12 14:47:50
Documents
1
Group Members
FORESITE CAPITAL FUND I, L.P.FORESITE CAPITAL FUND III, L.P.FORESITE CAPITAL MANAGEMENT I, LLCFORESITE CAPITAL MANAGEMENT II, LLCFORESITE CAPITAL MANAGEMENT III, LLCJAMES TANANBAUM

Document Format Files

Seq Description Document Type Size
1 SCHEDULE 13G/A v431161_sc13ga.htm SC 13G/A 118773
  Complete submission text file 0001144204-16-081316.txt   120589
Mailing Address 3344 N. TORREY PINES CT. SUITE 200 LA JOLLA CA 92037
Business Address 3344 N. TORREY PINES CT. SUITE 200 LA JOLLA CA 92037 (858) 875-8600
Orexigen Therapeutics, Inc. (Subject) CIK: 0001382911 (see all company filings)

IRS No.: 651178822 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13G/A | Act: 34 | File No.: 005-83422 | Film No.: 161417970
SIC: 2834 Pharmaceutical Preparations

Mailing Address 101 CALIFORNIA STREET, SUITE 4100 SAN FRANCISCO CA 94111
Business Address 101 CALIFORNIA STREET, SUITE 4100 SAN FRANCISCO CA 94111 415-877-4887
Foresite Capital Fund II, L.P. (Filed by) CIK: 0001594914 (see all company filings)

IRS No.: 901029166 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13G/A